Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s ...

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s ...

End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled

FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients

ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--Jun 24, 2025-

FDA expands Vizamyl label to include quantification and therapy monitoring

GE HealthCare’s amyloid PET imaging agent Vizamyl (flutemetamol) has won an FDA nod for expanded indications on June 24, 2025. The specific update adds quantification and therapy monitoring capabilities that competing products currently lack, positioning the diagnostic as an enabler for the rapidly growing anti-amyloid therapy market. At present, there are two disease-modifying anti-amyloid therapies… The post FDA expands Vizamyl label to includ…

FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.